Lv51
900 积分 2024-11-15 加入
Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial
3天前
已完结
Redefining stage IVB cervical cancer: The unique prognosis of distant lymph node metastasis which is comparable to stage IIIC
4天前
已完结
Reasons for first-line maintenance therapy discontinuation among patients with newly diagnosed advanced ovarian cancer treated in real-world settings
4天前
已关闭
Cancer burden and control in China: landscape, trends and challenges
5天前
已完结
Phase II study of maintenance niraparib rechallenge plus bevacizumab in patients with platinum-sensitive, recurrent ovarian cancer previously treated with a poly (ADP-ribose) polymerase inhibitor (KGOG-3056/NIRVANA-R)
5天前
已关闭
Phase II study of maintenance niraparib rechallenge plus bevacizumab in patients with platinum-sensitive, recurrent ovarian cancer previously treated with a poly (ADP-ribose) polymerase inhibitor (KGOG-3056/NIRVANA-R)
6天前
已关闭
Research Progress on the Combination of PARP Inhibitors (PARPi) and Immune Checkpoint Inhibitors (ICIs)
12天前
已完结
Discovery of 2-{4-[(3S)-Piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): A Novel Oral Poly(ADP-ribose)polymerase (PARP) Inhibitor Efficacious in BRCA-1 and -2 Mutant Tumors
18天前
已完结
Recent advances in the early detection of ovarian cancer
1个月前
已完结
Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu
1个月前
已完结
皖公网安备34019202002308
